{
    "id": 25725,
    "fullName": "CDH2 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "CDH2 positive indicates the presence of the CDH2 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 1000,
        "geneSymbol": "CDH2",
        "terms": [
            "CDH2",
            "CD325",
            "CDHN",
            "CDw325",
            "NCAD"
        ]
    },
    "variant": "positive",
    "createDate": "11/04/2016",
    "updateDate": "11/04/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9159,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with esophagus squamous cell carcinoma treated with ADH-1 demonstrated a partial response, which was sustained for six months (PMID: 22280327).",
            "molecularProfile": {
                "id": 26758,
                "profileName": "CDH2 positive"
            },
            "therapy": {
                "id": 4916,
                "therapyName": "ADH-1",
                "synonyms": null
            },
            "indication": {
                "id": 3748,
                "name": "esophagus squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6940,
                    "pubMedId": 22280327,
                    "title": "Phase I clinical trial of Exherin (ADH-1) in patients with advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22280327"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9158,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ADH-1 treatment led to disease control (stable disease or partial response) in 24% (6/25) of patients with advanced solid tumors demonstrating positive or unknown CDH2 tumor status (PMID: 22280327).",
            "molecularProfile": {
                "id": 26758,
                "profileName": "CDH2 positive"
            },
            "therapy": {
                "id": 4916,
                "therapyName": "ADH-1",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6940,
                    "pubMedId": 22280327,
                    "title": "Phase I clinical trial of Exherin (ADH-1) in patients with advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22280327"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26758,
            "profileName": "CDH2 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}